One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
IDEXX Laboratories, Inc. (IDXX): score, valuation & FAQ
IDEXX Laboratories, Inc. (IDXX) is a Diagnostics & Research company that scores 69.3 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (B+), while PEG (D) rate weaker. On valuation, IDXX sits about 224% above our discounted-cash-flow fair value — the current price implies roughly 41% annual free-cash-flow growth over the next decade.
Is IDXX a good stock to buy?
Bull Rankings scores IDXX 69.3 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by Rev (B+). A score is a quantitative screen of IDEXX Laboratories, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does IDXX score 69.3 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). IDXX earns its highest marks on Rev (B+), and is held back by PEG (D). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is IDXX overvalued or undervalued?
Based on $567.44, IDXX sits about 224% above our discounted-cash-flow fair value — the current price implies roughly 41% annual free-cash-flow growth over the next decade. It trades at a 42.4x× P/E (graded C+). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in IDXX?
The market is already pricing in aggressive expectations: a P/E of 41.7 and a PEG of 3.46 imply future growth far outpacing the current 13.1% revenue expansion, while a beta of 1.55 adds volatility. A slowdown in veterinary spend or margin erosion would force the stock to re‑price, and a rise in debt‑to‑equity above 0.71 would amplify financial risk. Confirmation of the bear case would be a miss on revenue growth or margin in the next earnings release.
New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.